Disease · MONDO_0005327

hip fracture

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hip fracture. Diseases, record MONDO_0005327. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005327

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hip fracture; Open Targets
Open Targets ID: MONDO_0005327; Open Targets
Other names: Fractures, Hip, Fractures, Intertrochanteric, Fractures, Subtrochanteric, Fractures, Trochanteric, Hip Fractures, Intertrochanteric Fractures, Subtrochanteric Fractures, Trochanteric Fractures; Open Targets
MeSH: D006620; MeSH
Highest stage of its drugs: Approval, for 2 of its 38 drugs, from PMDA; Open Targets

Drugs38

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EDOXABAN	CHEMBL1269025	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
ENOXAPARIN SODIUM	CHEMBL1201476	Oligosaccharide	Approval	PMDA	1	0	0	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
TERIPARATIDE	CHEMBL525610	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
FERROUS SULFATE	CHEMBL1200830	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
TESTOSTERONE	CHEMBL386630	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROXYETHYL STARCH 130/0.4	CHEMBL2108701		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AMINO ACIDS	CHEMBL1201498		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 38

See all 38 drugs

Targets70

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
OPRM1	Mu-type opioid receptor	4	Mu opioid receptor agonist	Unknown	https://conductscience.org/library/genes/4988	Drugs and targets
AR	Androgen receptor	3	Androgen Receptor agonist; Androgen Receptor modulator	Phase 3	https://conductscience.org/library/genes/367	Drugs and targets
SCN4A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
ADRA2A	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets

1 to 10 of 70

See all 70 targets

Trials36

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01081678	Study To Assess FRacTure Healing With SclerosTin Antibody - Hip	Phase 2	332	2019-05-02	Fracture Healing	ROMOSOZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02938923	Starting a Testosterone and Exercise Program After Hip Injury	Phase 3	129	2025-02-04	Hip Fracture, Frailty, Sarcopenia	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT04591353	Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty	Phase 3	122	2023-02-17	Total Hip Arthroplasty	LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT02578095	Acute Hip Fracture Study in Patients 65 Years or Greater	Phase 2	108	2025-12-29	Hip Fractures	VK5211	Its record names the disease	ClinicalTrials.gov
NCT01950169	Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture	Not applicable	79	2021-04-14	Hip Fracture	RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00393848	Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery	Phase 2	40	2014-06-02	Hip Fracture, Osteoarthritis, Femur Head Necrosis	KETOCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT06452147	Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)	Not applicable	1,860		Anesthesia, Hip Fractures, Dementia, Cognitive Impairment, Cognitive Decline	BUPIVACAINE, LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT01583660	Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture		800		Hip Fracture	ACETAMINOPHEN, CELECOXIB, OXYCODONE	Its record names the disease	ClinicalTrials.gov
NCT03092466	Early Femoral Block in Elderly With Hip Fracture	Not applicable	600		Hip Fractures	ROPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT02391883	Hip-Fracture Surgery on Patients in Clopidogrel Therapy		356		Hip Fracture	CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 36

See all 36 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Investigational Group (PENG Block Group) vs Control Group: Total Patients Using Antiemetics After Surgery	17 of 56	19 of 56	112	NCT04591353	Trial comparisons
Investigational Group (PENG Block Group) vs Control Group: deaths from any cause	0 of 56	0 of 56	112	NCT04591353	Trial comparisons
Investigational Group (PENG Block Group) vs Control Group: serious adverse events	0 of 56	0 of 56	112	NCT04591353	Trial comparisons

Papers from its trials35

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32231802	RESULT	1	PubMed
29629009	RESULT	1	PubMed
27871553	RESULT	1	PubMed
27787895	RESULT	1	PubMed
27717957	RESULT	1	PubMed
26443577	RESULT	1	PubMed
20630042	RESULT	1	PubMed
20613475	RESULT	1	PubMed
19926634	RESULT	2	PubMed
19054201	RESULT	1	PubMed

1 to 10 of 35

See all 35 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005327

GET https://conductscience.org/api/diseases/v1/MONDO_0005327/drugs?page=2

API reference For AI assistants